herp
simplex
viru
type
envelop
doublestrand
dna
viru
belong
herpesvirida
famili
viru
common
human
pathogen
main
caus
oral
infect
affect
mouth
lip
addit
infecti
agent
sever
diseas
includ
recurr
cold
sore
keratoconjunct
lifethreaten
herp
enceph
follow
primari
infect
hsv
establish
infect
neuron
sensori
ganglia
may
becom
latent
bodi
nervou
system
viru
protect
host
immun
system
latent
state
reactiv
sever
factor
hormon
chang
ultraviolet
uv
light
mainli
stress
treatment
infect
caus
includ
use
drug
acyclovir
valacyclovir
famciclovir
penciclovir
cidofovirar
pharmacokinet
limit
drug
difficult
transport
affect
tissu
induc
nontherapeut
drug
level
moreov
longterm
treatment
may
lead
select
resist
hsv
addit
concern
mainli
immunocompromis
patient
emphas
need
altern
strategi
chloroquin
diphosph
cq
antimalari
drug
use
firstlin
treatment
plasmodium
vivax
plasmodium
oval
plasmodium
malaria
plasmodium
falciparum
infect
addit
antimalari
activ
cq
use
treat
chronic
diseas
rheumatoid
arthriti
system
lupu
erythematosu
recent
drug
also
attract
attent
due
anticanc
antivir
activ
context
cq
hydrophil
drug
low
toxic
shown
limit
reach
effect
intracellular
concentr
one
main
disadvantag
convent
malaria
treatment
nonspecif
target
intracellular
parasit
lead
high
dose
administr
result
toxic
expect
antimalari
drug
efficaci
antivir
drug
cq
depend
cellular
uptak
attempt
solv
limit
cq
nanodrug
deliveri
system
ndd
known
chang
drug
biodistribut
decreas
toxic
modifi
drug
releas
rate
mainli
drug
target
affect
tissuescel
among
ndd
polymer
nanoparticl
np
promis
approach
improv
drug
uptak
specif
cell
line
advantag
includ
higher
stabil
biolog
fluid
easi
storag
condit
polyest
poli
lactic
acid
pla
biocompat
biodegrad
polym
complet
elimin
bodi
natur
metabol
pathway
furthermor
pla
polym
approv
food
drug
administr
fda
wide
use
biomateri
prepar
nanoparticl
drug
deliveri
sever
method
appli
prepar
np
divid
two
categori
base
dispers
preform
polym
base
polymer
monom
consid
dispers
preform
polym
solvent
evapor
method
spontan
emulsificationsolv
diffus
method
wellconsolid
one
nanoprecipit
solvent
displac
method
onestep
procedur
control
interfaci
deposit
polym
displac
organ
aqueou
phase
due
fast
spontan
diffus
nanoparticl
format
occur
instantan
emulsificationsolv
evapor
method
twostep
procedur
organ
solut
emulsifi
aqueou
phase
use
highspe
homogen
ultrason
format
np
occur
due
polym
precipit
solvent
evapor
entrap
hydrophil
drug
insid
hydrophob
polymer
nanoparticl
easi
task
especi
use
nanoprecipit
method
inde
hydrophil
drug
weak
interact
polyest
pla
thu
drug
transport
organ
phase
outer
aqueou
phase
induc
low
entrap
effici
phenomenon
justifi
drawback
lesswel
protect
drug
degrad
faster
drug
releas
strategi
use
improv
encapsul
effici
hydrophil
molecul
polyest
nanoparticl
control
ph
aqueou
phase
chang
solvent
phase
use
high
drug
concentr
salt
addit
aqueou
phase
exampl
context
anti
activ
cq
specif
studi
report
singh
et
al
demonstr
possibl
mechan
action
cq
promis
antivir
drug
drug
charact
weak
base
contribut
increas
intracellular
ph
affect
viru
life
cycl
addit
cq
impair
gd
protein
transport
transgolgi
network
cell
membran
induc
format
defect
viral
particl
thu
studi
perform
improv
encapsul
effici
hydrophil
cq
biocompat
pla
nanoparticl
evalu
modul
drug
releas
affect
antihsv
activ
experiment
design
includ
differ
prepar
method
variat
polymerdrug
ratio
specif
paramet
ph
aqueou
phase
antihsv
perform
assess
use
vero
cell
chloroquin
diphosph
cq
poloxam
poloxam
purchas
sigmaaldrich
saint
loui
mo
usa
lpoli
lactic
acid
pla
inher
viscos
dl
purchas
lactel
absorb
birmingham
al
usa
dichloromethan
dcm
dielectr
constant
ethanol
etoh
aceton
ace
nmp
purchas
paulo
brazil
purifi
water
prepar
revers
osmosi
purif
equip
model
lx
gehaka
sao
paulo
brazil
reagent
analyt
grade
solut
contain
pla
differ
concentr
wv
inject
aqueou
phase
contain
poloxam
wv
magnet
stir
rpm
drug
concentr
fix
experi
result
drugpolym
ratio
cq
pla
ww
two
differ
alkalin
agent
test
modifi
ph
outer
phase
cq
pla
concentr
fix
wv
respect
organ
phase
wv
poloxam
concentr
remain
fix
wv
aqueou
phase
first
aqueou
phase
ph
adjust
use
sodium
hydroxid
naoh
second
test
aqueou
phase
produc
ad
sodium
bicarbon
ph
adjust
nanoparticl
also
prepar
use
adjust
emulsificationsolv
evapor
method
briefli
smallscal
liquidliquid
partit
procedur
perform
mix
ml
aqueou
solut
ph
ml
contain
cq
wv
ml
organ
phase
dcm
contain
pla
ww
obtain
cq
pla
ratio
ww
flask
stir
vortex
cycl
second
interv
min
cycl
partit
step
supernat
solut
remov
ml
organ
phase
contain
cq
pla
taken
inject
ml
aqueou
phase
ml
contain
surfact
poloxam
wv
magnet
stir
rpm
organ
aqueou
phase
previous
filter
use
membran
emulsif
produc
use
ultraturrax
equip
stir
ika
labortechnik
germani
min
evapor
solvent
magnet
stir
rpm
overnight
sampl
store
hermet
seal
glass
flask
size
zeta
potenti
measur
h
experi
perform
triplic
data
express
mean
standard
deviat
sd
amount
drug
organ
phase
analyt
determin
uv
spectrophotometri
nm
blank
nanoparticl
prepar
use
procedur
without
addit
cq
buffer
solut
experi
perform
triplic
data
express
mean
standard
deviat
sd
mean
particl
size
polydispers
index
pdi
assess
use
dynam
light
scatter
dl
particl
size
analyz
brookhaven
instrument
holtsvil
ny
us
nm
wavelength
detect
angl
zeta
potenti
potenti
measur
perform
equip
appli
field
strength
use
electrophoret
mobil
measur
perform
least
ten
determin
sampl
dilut
vv
purifi
water
experi
perform
triplic
data
express
mean
standard
deviat
sd
sampl
centrifug
g
use
ultracentrifug
filter
vivaspin
kda
drug
concentr
supernat
assess
use
uvvi
spectrophometri
method
nm
thermo
fisher
scientif
evolut
madison
wi
us
analys
perform
triplic
data
express
mean
standard
deviat
sd
encapsul
effici
ee
calcul
use
equat
drug
total
total
drug
amount
ad
drug
free
nonentrap
drug
supernat
centrifug
ee
drug
drug
free
drug
total
shape
surfac
drugfre
cqnp
observ
use
afm
imag
dispers
drop
cover
slip
dri
desicc
h
analyz
afm
shimadzu
tokyo
japan
room
temperatur
cantilev
noncontact
hz
scan
drug
releas
profil
cqnp
assess
vitro
assay
use
static
franz
vertic
diffus
cell
crown
scientif
sommervil
us
thermostat
hermet
seal
donor
compart
ml
formul
appli
separ
receptor
compart
use
dialysi
membran
cutoff
kda
sigmaaldrich
previous
hydrat
phosphat
buffer
ph
h
receptor
compart
fill
ml
buffer
phosphat
solut
adjust
ph
remain
magnet
stir
rpm
experi
specif
interv
aliquot
ml
taken
uv
spectrophotometri
analysi
nm
previous
valid
volum
freshli
buffer
solut
replac
medium
maintain
sink
condit
experi
also
perform
free
cq
aqueou
solut
control
analys
perform
triplic
data
express
mean
standard
deviat
sd
vero
cell
continu
cell
lineag
origin
kidney
african
green
monkey
kindli
donat
depart
intern
medicin
school
medicin
sao
paulousp
brazil
cell
maintain
cultur
cultur
medium
lglutamin
invitrogen
new
york
ny
us
supplement
fetal
bovin
serum
fb
antibioticantimycot
solut
triptos
phosphat
viru
strain
ko
kindli
provid
dra
maria
oliveira
msc
laurita
boff
colleg
pharmaci
feder
univers
santa
catarina
brazil
viru
propag
titrat
plaqueform
unit
assay
pfu
vero
cell
viral
stock
store
use
viabil
vero
cell
follow
exposur
h
differ
concentr
cq
cqnp
blank
nanoparticl
bnp
assess
use
bromid
mtt
method
briefli
vero
cell
cellswel
cultur
plate
medium
fb
maintain
h
cell
expos
decreas
concentr
cq
twofold
serial
dilut
nanoparticl
rang
solut
suspend
medium
supplement
fb
cytotox
assay
cq
dissolv
filter
steril
filter
sartoriu
cqnp
bnp
filter
steril
filter
sartoriu
h
incub
medium
collect
mtt
sigma
germani
ref
solut
mg
ad
per
well
plate
incub
h
posteriorli
dmso
ad
well
absorb
measur
nm
micropl
reader
epoch
model
measur
carri
triplic
three
plate
three
replic
dilut
cell
viabil
defin
comparison
untreat
control
rel
cell
viabil
sampl
treat
well
respect
control
well
estim
equat
cell
viabil
test
b
control
test
b
control
absorb
treat
sampl
control
sampl
respect
experi
set
triplic
determin
cytotox
concentr
valu
nonlinear
regress
concentrationrespons
curv
use
defin
concentr
reduc
cell
viabil
compar
untreat
control
assay
titer
viru
prepar
pfuml
plaqu
reduct
assay
vero
cell
monolay
infect
pfuwel
h
inoculum
nonattach
viral
particl
remov
cell
wash
pb
final
infect
cell
treat
accord
assay
cq
cqnp
bnp
test
antivir
activ
plaqu
reduct
assay
assay
perform
accord
standard
method
describ
calda
do
santo
berampinto
vero
cell
seed
plate
cellswel
infect
dilut
medium
without
supplement
pfuwel
h
except
neg
control
incub
viral
inoculum
remov
monolay
wash
pb
subsequ
medium
contain
carboxymethylcellulos
cmc
saint
loui
mo
usa
overlay
ad
plate
incub
h
overlaid
duplic
contain
cmc
presenc
absenc
differ
noncytotox
concentr
test
compound
plate
incub
h
period
medium
well
remov
cell
stain
naphthol
blueblack
sigma
number
plaqu
well
count
measur
carri
duplic
two
plate
three
replic
dilut
percent
inhibitori
concentr
determin
use
equat
inhibit
number
plaqu
testednumb
viral
control
plaqu
concentr
treatment
reduc
viral
replic
calcul
regress
analysi
doserespons
curv
gener
data
viral
control
consid
inhibit
receiv
treatment
ratio
valu
calcul
obtain
select
index
si
sampl
acyclovir
acv
pharma
nostra
china
use
posit
control
experiment
valu
express
mean
standard
deviat
sd
pairwis
comparison
analyt
data
perform
use
student
ttest
antivir
assay
cell
viabil
multipl
comparison
perform
use
analysi
varianc
anova
p
signific
level
follow
bonferroni
test
dunnett
test
small
cqnp
success
prepar
use
paramet
select
nanoprecipit
method
experi
bnp
produc
use
experiment
paramet
absenc
drug
np
nm
neg
zeta
potenti
narrow
particl
size
distribut
pdi
identifi
test
formul
tabl
three
differ
cq
pla
ratio
test
formul
use
slightli
acid
aqueou
phase
ph
howev
ee
level
less
identifi
sampl
decreas
accord
cq
pla
ratio
addit
zeta
potenti
becom
neg
mv
mv
due
phdepend
solubl
charact
cq
two
alkalin
aqueou
phase
test
aim
improv
ee
formul
tabl
use
naoh
alkal
agent
formul
possibl
achiev
ee
hand
formul
produc
use
induc
ee
approach
adjust
emulsificationsolv
evapor
method
use
appli
smallscal
liquidliquid
partit
provid
maximum
concentr
chloroquin
free
base
cqfb
organ
phase
experi
cqfb
amount
organ
phase
analyt
control
use
uv
spectrophotometri
averag
level
cqfb
dissolv
dcm
achiev
np
nm
neg
zeta
potenti
pdi
produc
use
select
paramet
tabl
strategi
induc
cqfb
immisc
organ
phase
structur
droplet
dispers
alkalin
aqueou
solut
ph
provid
excel
ee
formul
formul
select
studi
shape
surfac
bnp
cqnp
formul
produc
emulsificationsolv
evapor
method
assess
use
atom
forc
microscopi
afm
imag
figur
nanoparticl
formul
shown
spheric
shape
slight
smooth
surfac
drug
releas
experi
perform
formul
produc
emulsif
solvent
evapor
method
drug
releas
profil
shown
figur
cqload
np
exhibit
desir
slow
drug
releas
profil
compar
free
cq
drug
aqueou
solut
data
subject
four
differ
diffus
kinet
linear
model
includ
firstord
model
figur
bhaskar
model
figur
freundlich
model
figur
parabol
model
figur
drug
releas
rate
constant
k
correl
coeffici
r
distinct
kinet
model
shown
tabl
parabol
diffus
model
fit
cq
releas
pla
nanoparticl
better
other
mathemat
model
give
linear
correl
coeffici
experi
antivir
activ
cytotox
cq
cqnp
formul
bnp
vero
cell
use
mtt
assay
evalu
figur
bnp
shown
cytotox
effect
concentr
rang
seven
h
h
figur
b
hand
drug
cq
exhibit
cytotox
concentrationdepend
profil
timedepend
figur
b
addit
serial
dilut
suggest
signific
cytotox
treat
cell
formul
concentr
h
experi
cqnp
consid
serial
dilut
evalu
effect
np
drug
toxic
condit
anterior
experi
figur
concentr
use
start
point
serial
dilut
cell
viabil
achiev
treatment
cq
observ
cq
figur
b
cqnp
sampl
also
exhibit
concentr
timepend
cytotox
profil
figur
np
increas
cytotox
effect
drug
similar
concentr
rang
suggest
greater
drug
uptak
cell
averag
identifi
freecq
drug
threefold
cqnp
tabl
addit
cell
viabil
observ
concentr
level
lower
achiev
fundament
choos
concentr
rang
use
vitro
infecti
assay
bnp
cq
cqnp
activ
bnp
cq
cqnp
formul
infect
vero
cell
assess
use
standard
plaqu
reduct
assay
valu
tabl
determin
nonlinear
regress
concentrationrespons
curv
expect
bnp
show
antiherpet
activ
test
concentr
rang
averag
si
valu
assay
cq
consider
larger
cqnp
three
distinct
paramet
evalu
demonstr
superior
efficaci
cqnp
experi
aim
evalu
antiherpet
activ
formul
perform
viru
adsorpt
acyclovir
firstlin
drug
treatment
hsv
infect
use
posit
control
wherea
untreat
infect
cell
use
neg
control
treatment
differ
concentr
sampl
h
postinfect
pi
show
dosedepend
viral
inhibit
cq
cqnp
p
figur
result
suggest
cq
show
abil
inhibit
viral
replic
wherea
cqnp
effect
observ
figur
concentr
rang
cqnp
inhibitori
activ
consider
higher
cq
p
moreov
smaller
differ
p
observ
concentr
treatment
vero
infect
cell
test
concentr
bnp
show
signific
activ
viru
figur
inhibit
viral
replic
significantli
differ
posit
control
p
studi
feasibl
biodegrad
pla
nanoparticl
promis
approach
improv
antivir
activ
chloroquin
diphosph
cq
investig
small
biodegrad
nanoparticl
abil
overcom
biolog
barrier
efflux
cotransport
protein
cell
membran
brainblood
barrier
context
vero
cell
infect
common
human
pathogen
herp
simplex
viru
type
antivir
activ
cq
report
literatur
howev
activ
yet
well
describ
inde
due
similar
characterist
previou
describ
viru
infect
studi
use
cq
promis
effect
infect
could
hypothes
use
drug
addit
encapsul
biodegrad
biocompat
np
could
solv
nonspecif
target
intracellular
pathogen
biocompat
biodegrad
poli
lactic
acid
pla
chosen
purpos
howev
polym
hydrophob
polyest
produc
np
encapsul
hydrophil
drug
cq
consist
interest
challeng
thu
two
differ
method
prepar
nanoparticl
well
appli
class
polym
care
test
small
size
system
drug
encapsul
effici
ee
select
main
perform
paramet
physicochem
properti
formul
produc
nanoprecipit
method
reveal
drugpolym
ratio
directli
affect
particl
size
ee
tabl
expect
particl
size
increas
accord
polym
concentr
organ
phase
effect
gener
improv
ee
hydrophob
drug
contrast
fact
formul
show
low
ee
decreas
polym
increment
chloroquin
diphosph
cq
lowweight
drug
multipl
pka
solubl
behavior
depend
ph
ph
hydrophil
compound
unabl
favor
interact
hydrophob
polyest
pla
increment
pla
lead
drug
displac
organ
phase
aqueou
phase
result
low
entrap
effici
experiment
result
formul
onethre
provid
import
achiev
relationship
solubl
behavior
cq
interact
pla
thu
ph
aqueou
phase
initi
control
ph
adjust
alkalin
rang
increas
nonion
fraction
cq
strategi
potenti
improv
ee
mainli
consid
hydrophil
drug
central
drugpolym
ratio
chosen
purpos
alkalin
aqueou
phase
ph
naoh
formul
made
possibl
improv
averag
ee
alkalin
aqueou
phase
ph
formul
prove
effici
induc
averag
ee
previou
studi
report
cq
degrad
acceler
naoh
media
hydrolysi
mechan
hypothesi
drug
precipit
aqueou
phase
due
strongest
alkalin
ph
also
consid
dispers
prepar
ph
show
neg
zeta
potenti
mv
mv
due
termin
acid
carboxyl
group
pla
tabl
two
main
stabil
mechan
colloid
suspens
consid
electrostat
repuls
ad
ionic
stabil
steric
stabil
achiev
nonion
stabil
medium
formul
describ
present
studi
stabil
use
poloxam
nonion
copolym
stabil
agent
steric
stabil
domin
solvat
effect
thu
ph
chang
chang
drugpolym
ratio
necessari
induc
monoton
chang
zeta
potenti
occur
approach
tabl
valu
slightli
increas
formul
largest
pla
content
ph
increas
alkalin
rang
eight
eleven
zeta
potenti
remain
neg
expect
select
paramet
emulsificationsolv
evapor
method
induc
larger
particl
compar
produc
nanoprecipit
techniqu
tabl
np
shown
neg
zeta
potenti
narrow
particl
size
pdi
mean
diamet
nm
best
result
use
nanoprecipit
method
reach
use
cq
pla
ratio
ww
aqueou
solut
ph
work
condit
repeat
emulsificationsolv
evapor
method
excel
averag
ee
level
fact
corrobor
success
partit
cqfb
organ
phase
import
alkalin
aqueou
phase
maintain
drug
polym
droplet
emuls
ph
aqueou
phase
ph
assur
maximum
nonion
chloroquin
amin
group
compar
previou
test
aqueou
phase
ph
contact
organ
immisc
solvent
dcm
phase
equilibrium
ioniz
nonion
speci
cq
aqueou
phase
chang
constantli
partit
nonion
speci
drug
interfac
final
organ
solvent
displac
nonion
molecul
drug
occur
exhaust
transport
total
amount
organ
phase
suggest
exampl
figur
mass
ratio
maintain
two
phase
could
explain
principl
mass
conserv
formul
select
experi
afm
imag
figur
suggest
spheric
np
slightli
smooth
surfac
also
possibl
observ
np
rang
nm
corrobor
dl
experi
hoo
et
al
report
differ
among
afm
dl
experi
mainli
due
differ
sampl
prepar
procedur
induc
particl
agglomer
formul
abl
gener
desir
slow
drug
releas
corrobor
drugload
experi
figur
consid
emulsificationsolv
evapor
method
ee
level
superior
consid
excel
induc
slow
drug
releas
profil
adjust
parabol
diffus
mathemat
model
r
tabl
fact
suggest
diffusioncontrol
transport
cq
polymer
matrix
np
addit
import
note
best
knowledg
data
literatur
describ
slow
chloroquin
releas
pla
nanoparticl
previou
studi
shown
releas
hydroxyl
chloroquin
sulphat
np
ee
h
encapsul
chloroquin
diphosph
describ
chitosan
np
prepar
ionic
gelat
techniqu
ee
induc
releas
drug
h
present
studi
amount
drug
releas
h
much
slower
previous
cite
studi
approach
residu
amount
nonion
speci
cq
load
pla
nanoparticl
seem
strongli
interact
pla
matrix
parabol
model
fit
experiment
data
much
better
r
figur
suggest
drug
releas
control
diffus
first
moment
howev
eros
polymer
matrix
particl
also
consid
releas
residu
entrap
drug
could
occur
second
moment
abil
colloid
nanocarri
preserv
entrap
drug
polymer
matrix
promis
characterist
drug
target
intend
specif
affect
cell
tissu
mainli
consid
intern
nanoparticl
endocytosi
assess
physicochem
feasibl
properti
formul
suggest
interest
promis
pla
np
system
cq
target
thu
studi
evalu
cytotox
activ
perform
cell
viabil
experi
demonstr
absenc
cytotox
effect
blank
pla
np
bnp
test
concentr
rang
h
figur
incub
figur
addit
possibl
suggest
pla
np
improv
cq
uptak
cqnp
shown
cell
viabil
level
lower
observ
free
cq
drug
test
concentr
rang
figur
identifi
cq
cqnp
tabl
corrobor
fact
biocompat
noncytotox
concentr
rang
cq
np
select
use
follow
experi
cell
posit
control
acyclovir
use
experi
noncytotox
concentr
firstlin
treatment
hsv
infect
consist
use
acycl
analogu
guanosin
deriv
drug
distinct
metabol
pathway
act
block
synthesi
viral
dna
inhibit
dna
polymeras
three
phosphoryl
step
requir
acyclovir
action
first
phosphoryl
perform
viral
thymidin
kinas
tk
encod
gene
subsequ
phosphoryl
step
perform
host
cell
kinas
current
strain
resist
acyclovir
presenc
mutat
andor
viral
gene
respons
encod
tk
dna
polymeras
detect
emerg
new
strain
resist
convent
drug
highlight
need
new
effect
antivir
therapi
novel
mechan
action
thu
new
antiherpet
drug
differ
mechan
action
achiev
context
work
focus
role
cq
highlight
lysosomotrop
drug
among
molecul
prove
antivir
activ
cq
shown
pronounc
antivir
action
differ
virus
studi
report
koyama
uchida
demonstr
multipl
strain
hf
vero
cell
inhibit
ammonium
chlorid
chloroquin
also
observ
matur
intracellular
viru
prevent
immedi
addit
weak
base
late
stage
infect
indic
site
inhibit
weak
base
one
step
matur
process
present
studi
show
vero
cell
infect
treat
cq
cqnp
viral
replic
inhibit
h
figur
concentr
rang
pla
np
significantli
improv
cq
figur
cqnp
induc
consider
lesser
identifi
cq
tabl
addit
cqnp
induc
similar
viral
inhibit
observ
posit
control
acyclovir
figur
well
report
polymer
nanoparticl
chang
drug
bioavail
biodistribut
reduc
side
effect
improv
drug
efficaci
previou
studi
also
demonstr
nanoparticl
biocompat
system
use
cell
cultur
approach
mechan
cq
action
infect
cell
still
fulli
solv
studi
propos
chang
lysosom
ph
inhibit
viral
packag
matur
transgolgi
network
thu
consid
report
resist
strain
acyclovir
cqload
pla
nanoparticl
system
suggest
interest
promis
approach
viral
infect
studi
found
nanoprecipit
best
method
encapsul
hydrophil
cq
drug
compar
emulsificationsolv
evapor
howev
shown
experi
tri
differ
strategi
consid
import
paramet
improv
drug
load
biocompat
pla
nanoparticl
improv
activ
chloroquin
data
demonstr
effici
nanoencapsul
method
use
emulsificationsolv
evapor
abl
produc
np
high
ee
hydrophil
drug
abl
induc
slow
cq
releas
experiment
result
also
reveal
cqnp
induc
similar
inhibit
observ
first
line
drug
acyclovir
addit
could
suggest
pla
np
improv
cq
uptak
infect
vero
cell
consist
promis
approach
solv
drug
limit
overcom
biolog
barrier
target
affect
cell
studi
requir
corrobor
hypothesi
use
anim
model
complex
test
assess
possibl
strategi
function
np
